Clinical Research Directory

Inclusion Criteria: * Patient at least 18 years old * Patient who read and understood the newsletter and signed the consent form * Renal cell carcinoma histologically proven stage IV * Metastatic stage proven on CT, synchronous or metachronous examination * Patient operated on or not from the primary tumor * Eligible for first-line systemic therapy with Sunitinib-targeted therapy for oncology urology * Affiliation to a social security scheme * Effective contraception (as defined by the WHO) for at least 3 months at the inclusion visit, during treatment and for 1 month after the end of the research (negative pregnancy test) * Postmenopausal woman: confirmatory diagnosis (amenorrhea not clinically induced for more than 12 months at inclusion visit) * General condition WHO 0 to 2 * Life expectancy estimated at more than 6 months at baseline Exclusion Criteria: * Non-metastatic disease * Other cancer proven histologically, or in complete remission for less than 2 years * Contraindication to SUTENT 50 mg hard capsules: Hypersensitivity to the active substance or to any of the excipients * History of immunotherapy treatment for kidney cancer, previous treatment with targeted therapies for the same or previous cancer * Pregnant or lactating woman or wishing to breastfeed within 6 months after the last treatment or no known contraception, * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-guardianship or curatorship * Patient currently involved in an interventional trial